AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.74 |
Market Cap | 168.90M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.4 |
PE Ratio (ttm) | -1.86 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.74 |
Volume | 877,954 |
Avg. Volume (20D) | 1,790,814 |
Open | 0.75 |
Previous Close | 0.73 |
Day's Range | 0.73 - 0.77 |
52-Week Range | 0.52 - 1.54 |
Beta | undefined |
About VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the t...
Analyst Forecast
According to 2 analyst ratings, the average rating for VXRT stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 304.04% from the latest price.